logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Obesity

    Medications for Obesity

    FiltersReset Filters
    9 results

    • amphetamine sulfate

      (Amphetamine Sulfate)
      Granules Pharmaceuticals Inc.
      Usage: Amphetamine sulfate tablets are indicated for narcolepsy, Attention Deficit Disorder with Hyperactivity in conjunction with a comprehensive treatment program, and as a short-term adjunct for exogenous obesity in patients not responding to other weight loss strategies.

    • amphetamine sulfate

      (amphetamine sulfate)
      Lannett Company, Inc.
      Usage: Amphetamine sulfate tablets (5 mg and 10 mg) are indicated for narcolepsy, Attention Deficit-Disorder with Hyperactivity as part of a comprehensive treatment program, and short-term management of exogenous obesity as an adjunct to a caloric restriction regimen in patients unresponsive to other therapies.

    • contrave

      (naltrexone hydrochloride and bupropion hydrochloride)
      Nalpropion Pharmaceuticals LLC
      Usage: CONTRAVE is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) with weight-related comorbid conditions, as an adjunct to diet and exercise. Safety with other weight loss products is not established.

    • diethylpropion hydrochloride

      (Diethylpropion Hydrochloride)
      Lannett Company, Inc.
      Usage: Diethylpropion hydrochloride extended-release tablets, 75 mg, are indicated for short-term management of exogenous obesity in patients with a BMI of 30 kg/m² or higher who have not responded to diet and exercise alone. It is intended for use as monotherapy.

    • lomaira

      (Phentermine Hydrochloride)
      KVK-Tech Inc
      Usage: LOMAIRA™ tablets are indicated for short-term weight reduction as an adjunct to exercise, behavioral modification, and caloric restriction in patients with a body mass index (BMI) of ≥30 kg/m², or ≥27 kg/m² with risk factors like controlled hypertension, diabetes, or hyperlipidemia.

    • phentermine hydrochloride

      (phentermine hydrochloride)
      SUNRISE PHARMACEUTICAL, INC.
      Usage: Phentermine hydrochloride capsules are indicated as a short-term adjunct to weight reduction programs, including exercise, behavioral modification, and caloric restriction, for patients with exogenous obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with risk factors like hypertension, diabetes, or hyperlipidemia).

    • saxenda

      (liraglutide)
      Novo Nordisk
      Usage: SAXENDA is indicated for weight management in adults and patients aged 12 and older with obesity (≥60 kg) or with overweight plus a weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Coadministration with other liraglutide-containing products is not recommended.

    • wegovy

      (semaglutide)
      Novo Nordisk
      Usage: WEGOVY is indicated for reducing major cardiovascular event risk in adults with obesity or overweight and cardiovascular disease, and for long-term weight reduction in adults and pediatric patients (12 years and older) with obesity or adults with overweight and weight-related comorbidities, alongside diet and exercise.

    • xenical

      (orlistat)
      H2-Pharma LLC
      Usage: XENICAL is indicated for managing obesity through weight loss and maintenance, alongside a reduced-calorie diet. It also helps prevent weight regain post-weight loss and is suitable for obese patients with a BMI ≥30 kg/m² or ≥27 kg/m² with additional risk factors like hypertension, diabetes, or dyslipidemia.